Coherus Oncology (CHRS) SEC Filings: History & Chart

Coherus Oncology, Inc.(CHRS)

Biotechnology · Redwood City, CA

$1.07-0.05 (-4.46%)

Delayed quote: Oct 6, 2026, 11:15 AM EDT

About Coherus Oncology, Inc.

Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.

Redwood City, CA

144 employees

www.coherus.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Dennis Lanfear

View full financials

Form	Filing Date	Accepted	Document
8-K	Aug 28, 2026	Aug 28, 2026	View filing
424B5	Aug 28, 2026	Aug 28, 2026	View filing
424B3	Aug 28, 2026	Aug 28, 2026	View filing
8-K	Aug 17, 2026	Aug 17, 2026	View filing
8-K	Aug 17, 2026	Aug 17, 2026	View filing
S-8	Aug 5, 2026	Aug 5, 2026	View filing
10-Q	Aug 5, 2026	Aug 5, 2026	View filing
8-K	Aug 5, 2026	Aug 5, 2026	View filing
SC 13G	Jul 27, 2026	Jul 27, 2026	View filing
8-K	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 9, 2026	Jun 9, 2026	View filing
4	Jun 9, 2026	Jun 9, 2026	View filing
4	Jun 9, 2026	Jun 9, 2026	View filing
4	Jun 9, 2026	Jun 9, 2026	View filing
4	Jun 9, 2026	Jun 9, 2026	View filing
4	Jun 9, 2026	Jun 9, 2026	View filing
4	Jun 9, 2026	Jun 9, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing
8-K	Jun 1, 2026	Jun 1, 2026	View filing
DEFA14A	May 28, 2026	May 28, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
10-Q	May 11, 2026	May 11, 2026	View filing
8-K	May 11, 2026	May 11, 2026	View filing
SC 13G/A	May 11, 2026	May 11, 2026	View filing
DEFA14A	May 5, 2026	May 5, 2026	View filing
SC 13G/A	Apr 29, 2026	Apr 29, 2026	View filing
SC 13G/A	Apr 27, 2026	Apr 27, 2026	View filing
ARS	Apr 20, 2026	Apr 20, 2026	View filing
DEF 14A	Apr 20, 2026	Apr 20, 2026	View filing

SEC Filings

Recent Filings